Valneva SE (NASDAQ:VALN - Get Free Report)'s stock price was down 4.6% during mid-day trading on Tuesday . The company traded as low as $8.43 and last traded at $8.43. Approximately 2,692 shares traded hands during trading, a decline of 76% from the average daily volume of 11,225 shares. The stock had previously closed at $8.84.
Wall Street Analyst Weigh In
A number of analysts have issued reports on VALN shares. Guggenheim cut their price target on shares of Valneva from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Friday, March 22nd. HC Wainwright reiterated a "buy" rating and set a $26.00 price target on shares of Valneva in a research note on Wednesday, May 8th.
Read Our Latest Report on Valneva
Valneva Price Performance
The stock's 50 day simple moving average is $7.88 and its 200-day simple moving average is $9.09. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.64 and a quick ratio of 2.22. The company has a market capitalization of $575.21 million, a PE ratio of -20.15 and a beta of 2.22.
Valneva (NASDAQ:VALN - Get Free Report) last released its earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of $0.20 by ($0.70). Valneva had a negative return on equity of 14.56% and a negative net margin of 15.88%. The firm had revenue of $45.12 million for the quarter, compared to analysts' expectations of $45.06 million. As a group, equities analysts forecast that Valneva SE will post -0.28 earnings per share for the current fiscal year.
Institutional Trading of Valneva
A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. increased its position in shares of Valneva SE (NASDAQ:VALN - Free Report) by 2.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 354,361 shares of the company's stock after buying an additional 9,361 shares during the period. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. 11.39% of the stock is currently owned by institutional investors.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Read More
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
